Pin1 as a marker for prostate cancer
AssigneePintex Pharmaceuticals, Inc.
InventorsLere Bao, Da Wang
Life of this patent
Estimating the term…
Abstract
This invention provides methods for diagnosing prostate cancer, methods for measuring the aggressiveness of prostate cancer, and methods for identifying prostate cancer likely to metastasize. The diagnostic and prognostic assays of this invention include methods involving the antibody-based detection of Pin1 and the amplification of Pin1 RNA. The diagnostic and prognostic assays of this invention may be used in combination with other methods of prostate cancer diagnosis including the PSA test, digital rectal exam, and Gleason prostate tumor grading system.
Claims9
A method of determining whether a subject is at risk of developing metastatic prostate cancer comprising,
- providing a biological sample from the subject comprising prostate cancer cells characterized as having a Gleason score of 6 to 7;
- and
- determining the level of Pin 1 polypeptide in the sample by detecting the binding of an antibody that specifically binds to a Pin1 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1, or an antigen binding fragment thereof, wherein the percentage of cells in the sample positive for antibody binding is indicative of whether the subject is at risk of developing metastatic prostate cancer.
A method of determining whether a subject is at risk of prostate tumor recurrence following surgery comprising,
- providing a biological sample from the subject comprising prostate cancer cells;
- and
- determining the level of Pin1 polypeptide in the sample by detecting the binding of an antibody that specifically binds to a Pin1 polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1, or an antigen binding fragment thereof,
- wherein the percentage of cells in the sample that are positive for antibody binding directly correlates with the risk of prostate cancer recurrence in the subject.
Dependencies are inferred from the claim text.